Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 31;21(3):936.
doi: 10.3390/ijms21030936.

Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency

Affiliations

Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency

Suvi Törmänen et al. Int J Mol Sci. .

Abstract

Chronic renal insufficiency (CRI) is characterized by increased endothelin 1 (ET-1) synthesis. We studied rat kidney endothelin receptor A (ETA) and receptor B (ETB) expressions after 12 and 27 weeks of 5/6 nephrectomy, and after 12 weeks of 0.3% adenine diet, representing proteinuric and interstitial inflammation models of CRI, respectively. Uric acid and calcium-phosphate metabolism were modulated after 5/6 nephrectomy, while ETA blocker and calcimimetic were given with adenine. Endothelin receptor mRNA levels were measured using RT-qPCR and protein levels using autoradiography (5/6 nephrectomy) or ELISA (adenine model). Both 12 and 27 weeks after 5/6 nephrectomy, kidney cortex ETA protein was increased by ~60% without changes in ETB protein, and the ETB:ETA ratio was reduced. However, the ETB:ETA mRNA ratio did not change. In the adenine model, kidney ETA protein was reduced by ~70%, while ETB protein was suppressed by ~95%, and the ETB:ETA ratio was reduced by ~85%, both at the protein and mRNA levels. The additional interventions did not influence the observed reductions in the ETB:ETA ratio. To conclude, unfavorable reduction in the ETB:ETA protein ratio was observed in two different models of CRI. Therefore, ETA blockade may be beneficial in a range of diseases that cause impaired kidney function.

Keywords: calcium; chronic kidney disease; chronic renal insufficiency; cinacalcet; creatinine; endothelin receptor A; endothelin receptor B; paricalcitol; phosphate; sitaxentan; uric acid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kidney medullary ETB (A) and ETA (B) receptor protein content, and the ETB:ETA protein ratio (C); and kidney cortical ETB (D) and ETA (E) receptor protein content, and the ETB:ETA receptor protein ratio (F) quantified using autoradiography in the twelve-week 5/6 nephrectomy model; NX, 5/6 nephrectomy; Sham, sham-operation; OXO, 2.0% oxonic acid diet; n = 12/group. Values are mean ± 95% confidence interval of the mean. Two-way ANOVA p-values for NX, OXO and their interaction are presented in the figures.
Figure 2
Figure 2
Representative original tracings of kidney ETB and ETA receptor autoradiography in the sham-operated and 5/6 nephrectomized rats in the twelve-week 5/6 nephrectomy model.
Figure 3
Figure 3
Kidney medullary ETB (A) and ETA (B) receptor protein content, and the ETB:ETA protein ratio (C); and kidney cortical ETB (D) and ETA (E) receptor protein content, and the ETB:ETA receptor protein ratio (F) quantified using autoradiography in the twenty-seven-week 5/6 nephrectomy model; NX, 5/6 nephrectomy; Sham, sham-operation; Ca, 3.0% calcium diet; Pi, 1.5% phosphate diet; Pari, 100 ng/rat of intraperitoneal paricalcitol three times weekly; n = 7−13/group. Values are mean ± 95% confidence interval of the mean. * p < 0.05 vs. Sham.
Figure 4
Figure 4
Kidney ETB (A) and ETA (B) receptor protein content, and the ETB:ETA receptor protein ratio (C) quantified using ELISA in the twelve-week adenine model; Control, control diet; Ade, 0.3% adenine diet; S, sitaxentan50 mg/kg/day; C, cinacalcet 20 mg/kg/day; SC, sitaxentan+cinacalcet; n = 12–20/group. Values are mean ± 95% confidence interval of the mean. * p < 0.05 vs. Control.

References

    1. Eckardt K.U., Coresh J., Devuyst O., Johnson R.J., Kottgen A., Levey A.S., Levin A. Evolving importance of kidney disease: From subspecialty to global health burden. Lancet. 2013;382:158–169. doi: 10.1016/S0140-6736(13)60439-0. - DOI - PubMed
    1. Kohan D.E., Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86:896–904. doi: 10.1038/ki.2014.143. - DOI - PMC - PubMed
    1. Longaretti L., Benigni A. Endothelin receptor selectivity in chronic renal failure. Eur. J. Clin. Invest. 2009;39:32–37. doi: 10.1111/j.1365-2362.2009.02119.x. - DOI - PubMed
    1. Heerspink H.J.L., Parving H.H., Andress D.L., Bakris G., Correa-Rotter R., Hou F.F., Kitzman D.W., Kohan D., Makino H., McMurray J.J.V., et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet. 2019;393:1937–1947. doi: 10.1016/S0140-6736(19)30772-X. - DOI - PubMed
    1. Vaneckova I., Hojna S., Kadlecova M., Vernerova Z., Kopkan L., Cervenka L., Zicha J. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non-diabetic chronic kidney disease: Is there still hope for the future? Physiol. Res. 2018;67:S55–S67. doi: 10.33549/physiolres.933898. - DOI - PubMed

MeSH terms